Skip to main content

Day: August 11, 2021

Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update

Reports Improved Outcomes in Phase 1b COVID-19 Study and Positive Trend in Peripheral Oxygenation in Phase 1b TCOM Study Expects to Announce Initial Indication and Regulatory Pathway in Fourth Quarter of 2021 and Initiate Clinical Outcome Study in First Half of 2022 Anticipates Cash Runway through 2023, Including Completion of TSC Phase 2b ProgramCHARLOTTESVILLE, Va., Aug. 11, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced financial results for the second quarter of 2021 and provided a business update. “We met our key milestones for the first half of 2021, completing and announcing topline results from our...

Continue reading

PHX Energy Receives TSX Approval for Renewal of Normal Course Issuer Bid

CALGARY, Alberta, Aug. 11, 2021 (GLOBE NEWSWIRE) — PHX Energy Services Corp. (“PHX Energy” or the “Corporation“) (TSX: PHX) today announced that the Toronto Stock Exchange (“TSX“) has accepted PHX Energy’s notice of intention to renew its normal course issuer bid for a further one-year term (the “NCIB“). The previous NCIB expired on August 13, 2021. Pursuant to the Corporation’s previous NCIB, the Corporation purchased in the open market through the facilities of the TSX and through other alternative Canadian trading platforms and cancelled an aggregate of 3,131,388 common shares (“Common Shares“) of the Corporation at an average price paid of $1.58 per Common Share, which represents all the approved securities available for repurchase under the previous NCIB. Under...

Continue reading

Avicanna Enters Partnership with Heritage Cannabis Holdings Corp. to Commercialize Evidence-Based Topical Products through Heritage’s Medical Cannabis Channels

Exclusive licensing of certain of Avicanna’s advanced and evidence-based CBD topical products including its deep tissue and skin care formulations. Heritage to lead medical sales and commercialization across non-competing medical channels in Canada under the Opticann brand./NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, Aug. 11, 2021 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an exclusive intellectual property...

Continue reading

Amerigo Reports Strong Net Income & Operating Cash Flow in Q2-2021

(Amounts in U.S. dollars except indicated otherwise) VANCOUVER, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; ARREF: OTC) (“Amerigo” or the “Company”) is pleased to announce financial results for the quarter ended June 30, 2021 (“Q2-2021”). Amerigo posted net income of $11.6 million, earnings per share (“EPS”) of $0.06 (Cdn$0.08), EBITDA1 of $23.4 million and quarterly operating cash flow before changes in working capital of $17.1 million. “Amerigo has again met operational objectives and posted another quarter of strong financial results. The Company generated $17.1 million in operating cash flow, improved its ending cash position to $53.1 million and reduced bank debt to $33.8 million”, said Aurora Davidson, Amerigo’s President and CEO. The information and data contained in this news release...

Continue reading

Perma-Fix Reports Financial Results and Provides Business Update for the Second Quarter of 2021

ATLANTA, Aug. 11, 2021 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the second quarter ended June 30, 2021. Mark Duff, President and CEO of the Company, commented, “As anticipated, revenues in the second quarter were primarily impacted by the ongoing effects of the COVID-19 pandemic, however we have begun to see activity pick up in third quarter and expect an improved second half of 2021. Despite the challenging environment, we reported net income of $3.0 million and maintained over $7 million of cash on the balance sheet. We experienced weakness in our Services Segment due to delays throughout the industry in evaluating bids and awarding procurements, also primarily due to the pandemic. Nevertheless, as we look at our...

Continue reading

Wesana Health Commences Functional Animal Study for Treatment of Traumatic Brain Injury

TORONTO and CHICAGO, Aug. 11, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the commencement of functional animal studies to determine effect of a psilocybin-based regimen on locomotor activity as well as anxiety and depression. Results from the anxiety and depression study are expected by early Q4 2021. “The locomotor study was designed to determine whether selected combinations of doses of the test product had any effects on locomotor activity and how pronounced this effect might be. Preliminary results, just released,...

Continue reading

Kaleido Biosciences Reports Second Quarter 2021 Financial Results

–On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter– –Kaleido and the COPD Foundation to collaborate on the development of KB109 in patients with COPD; plan to initiate Phase 2 clinical study in first quarter 2022– –Additional data from an observational clinical study of KB109 in patients with mild-to-moderate COVID-19 expected by end of third quarter– LEXINGTON, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today reported financial results for the second quarter ended June 30, 2021. “We have made considerable progress...

Continue reading

Pipestone Energy Corp. Reports Record Second Quarter 2021 Results and Provides an Operations Update

PIPESTONE DEVELOPMENT MAPPIPESTONE DEVELOPMENT MAPCALGARY, Alberta, Aug. 11, 2021 (GLOBE NEWSWIRE) — (PIPE – TSX) — Pipestone Energy Corp. (“Pipestone” or the “Company”) is pleased to report its Q2 2021 financial and operational results, as well as provide an update on its operations. During Q2 2021, Pipestone delivered record quarterly production and cash flow, underpinned by the continued efficient execution of its organic development program. The Company remains on track to generate free cash flow beginning in Q4 2021, with forecast annual free cash flow of $95 million in 2022 and $190 million in 2023 (US$65 WTI | C$2.50 AECO). SECOND QUARTER 2021 CORPORATE HIGHLIGHTS:Record average quarterly production of 23,336 boe/d (31% condensate, 46% total liquids), an 8% quarterly increase over Q1 2021 and a 39%...

Continue reading

White Gold Corp. Announces Commencement of Diamond Drilling and Completion of Structural Geological Interpretation at the Betty Project, Yukon

TORONTO, Aug. 11, 2021 (GLOBE NEWSWIRE) — White Gold Corp. (TSX.V: WGO, OTC – Nasdaq Intl: WHGOF, FRA: 29W) (the “Company”) is pleased to announce the commencement of the maiden diamond drilling program and the completion of a structural Geological interpretation at its Betty Property, contiguous to and 15km northeast of Western Copper and Gold Corporation’s Casino deposit (14.5 Moz gold & 7.1 Blbs copper of Measured & Indicated and 6.6 Moz gold and 3.3 Blb copper of Inferred), and 40km east of Newmont Corporation’s Coffee Gold deposit (2.17 Moz Indicated & 0.50 Moz Inferred gold). This is the second diamond drilling campaign of the company’s fully funded 2021 exploration program on its district scale 420,000 hectare land package, representing over 40% of the emerging White Gold District in Yukon, Canada,...

Continue reading

Osino Extends High-Grade Mineralization to Depth at Clouds East

Figure 1Section through Clouds East with recent intercepts and Grade Shell (≥0.4g/t Au) from April 2021 Mineral Resource Estimate (results shown in blue annotations are new assays not previously reported).Figure 2Subcrop Geology with Twin Hills Drill Collars and Highlights of Recent DrillingFigure 3Section through Bulge mineralization including Grade Shell (≥0.4g/t Au) from April 2021 Mineral Resource Estimate (results shown in blue annotation are new assays not previously reported).Further Expansion and Infill Assay Results From Bulge and Twin Hills CentralTwin Hills Gold Project, Namibia HighlightsClouds East high-grade shoot extended down to 200m below surface; grade and width of mineralization improves with depth and indicates the potential to substantially increase the size of the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.